Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate

DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma of the prostate * Metastatic disease * Progressive disease after prior antiandrogen therapy, as evidenced by at least 1 of the following parameters: * New osseous lesions on bone scan * Greater than 25% increase in the sum of the products of the longest perpendicular diameters of the lesions OR the appearance of new lesions on MRI or CT scan * Rising prostate-specific antigen (PSA) despite adequate medical or surgical castration therapy * Consecutive increase in PSA, determined by two separate measurements taken at least 1 week apart and confirmed by a third, and if necessary, a fourth measurement * PSA must be ≥ 5 ng/mL and ≥ 25% above the previous nadir * Measurable or evaluable disease * Serum testosterone ≤ 50 ng/dL * No confluent lesions involving axial and appendicular skeleton on bone scan ("superscan") PATIENT CHARACTERISTICS: Age * Over 18 Performance status * Karnofsky 70-100% Life expectancy * At least 6 months Hematopoietic * Absolute neutrophil count ≥ 2,000/mm\^3 * Hematocrit ≥ 30% * Hemoglobin ≥ 10 g/dL * Platelet count ≥ 150,000/mm\^3 * No serious hematologic illness that would preclude study participation Hepatic * AST ≤ 2 times upper limit of normal (ULN) * Bilirubin ≤ 1.5 times ULN * PTT normal * PT normal OR * INR normal * No serious hepatic illness that would preclude study participation Renal * Creatinine ≤ 2.5 mg/dL * Calcium ≤ 11 mg/dL * No serious renal illness that would preclude study participation Cardiovascular * No New York Heart Association class III or IV heart disease * No active angina pectoris * No prior deep vein thrombophlebitis within the past 3 months * No other serious cardiac illness that would preclude study participation Pulmonary * No pulmonary embolus within the past 3 months * No other serious respiratory illness that would preclude study participation Other * Fertile patients must use effective contraception * HIV negative * No serious CNS illness that would preclude study participation * No active serious infection not controlled by antibiotics * No other serious illness that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy * More than 2 weeks since prior red blood cell or platelet transfusions * More than 2 weeks since prior hematopoietic growth factors * No prior monoclonal antibody therapy except ProstaScint® * No other concurrent monoclonal antibody-based therapy * No concurrent medication to support platelet count (e.g., oprelvekin) Chemotherapy * More than 4 weeks since prior cytotoxic chemotherapy Endocrine therapy * See Disease Characteristics * Concurrent luteinizing hormone-releasing hormone (LHRH) analog allowed provided 1 of the following is true: * Treatment is maintained during study participation * Treatment is terminated at least 10 weeks (for 1-month depot preparations), 24 weeks (for 3-month depot preparations), or 32 weeks (for 4-month depot preparations) prior to study entry * More than 4 weeks since prior corticosteroids * More than 4 weeks since prior adrenal hormone inhibitors * Concurrent low-dose prednisone (≤ 5mg/day) for adrenal insufficiency allowed * No concurrent finasteride Radiotherapy * More than 4 weeks since prior radiotherapy * No prior radiotherapy to \> 25% of skeleton * No prior strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium-containing compounds (e.g., Metastron® or Quadramet®) Surgery * Not specified Other * More than 4 weeks since prior PC-SPES * More than 4 weeks since prior investigational therapy (medications or devices) * At least 1 week since prior aspirin and/or nonsteroidal anti-inflammatory agents possessing antiplatelet activity * At least 1 week since prior antiplatelet medication, including the following: * Abciximab * Cilostazol * Clopidogrel * Dipyridamole * Ticlopidine * No concurrent anticoagulant medications (for platelet count \< 50,000/mm\^3), including the following: * Dalteparin * Danaparoid * Enoxaparin * Heparin * Warfarin * No other concurrent investigational therapy